FindTrial
Sign In

Interferon alpha

DRUG11 trials

Sponsors

National Center for Research Resources (NCRR), M.D. Anderson Cancer Center, Eastern Cooperative Oncology Group, National Institute of Allergy and Infectious Diseases (NIAID), Università Politecnica delle Marche

Conditions

Acute respiratory infection (ARI)COVID-19 COVID-19 SARS-CoV-2Diabetes Mellitus, Type 1Hematologic NeoplasmsHepatitis CLung CancerLymphoma, T-CellMelanoma

Phase 2

Ingested Interferon Alpha: Prolongation or Permanence of the Honeymoon Phase in Newly Diagnosed Type 1 Diabetes Mellitus
NCT00005665
National Center for Research Resources (NCRR)Diabetes Mellitus, Type 1
Updated: 2005-06-24
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
CompletedNCT00038376
M.D. Anderson Cancer CenterHematologic Neoplasms, Lymphoma, T-Cell, Mycosis Fungoides
Start: 1990-05-08End: 2005-06-30Updated: 2018-10-29
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
CompletedNCT00062010
Eastern Cooperative Oncology GroupLung Cancer
Start: 2004-05-26End: 2012-08-31Updated: 2023-07-07
Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes
CompletedNCT00324389
National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis C
Start: 2006-05-31End: 2006-06-30Target: 2Updated: 2010-08-27
Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma
CompletedNCT00504140
M.D. Anderson Cancer CenterOsteosarcoma
Start: 1996-11-30End: 2009-03-31Updated: 2012-08-02

Phase 3

Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)
CompletedNCT00633542
Università Politecnica delle MarcheMultiple Myeloma
Start: 2003-06-30End: 2007-10-31Updated: 2008-03-12
Nasalferon in COVID-19
Active, not recruitingRPCEC00000399
Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 COVID-19 SARS-CoV-2
Start: 2021-11-22Target: 128Updated: 2026-03-30
Nasalferon in ARI
Active, not recruitingRPCEC00000407
Center for Genetic Engineering and Biotechnology (CIGB)Acute respiratory infection (ARI)
Start: 2022-09-01Target: 495Updated: 2026-03-30
Nasal recombinant human interferon alfa-2b in ARI
Active, not recruitingRPCEC00000412
Center for Genetic Engineering and Biotechnology (CIGB)acute respiratory infection
Start: 2023-02-01Target: 608Updated: 2026-03-30

Unknown Phase

Cognitive Effects of Interferon in Patients With Melanoma
CompletedNCT02074605
University of ArizonaMelanoma
Start: 2008-07-31End: 2010-05-31Updated: 2014-02-28
Expanded Clinical Use of Nasalferon in COVID-19
Active, not recruitingRPCEC00000396
Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 COVID-19 SARS-CoV-2
Start: 2021-11-15Target: 200Updated: 2026-03-30